A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

The announcement comes on the heels of a deal with the Trump administration to expand access to weight-loss drugs and reduce ...

New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease INDIANAPOLIS, Nov. 10, 2025 /PRNewswire/ -- For Tan ...

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

Eli Lilly is currently redefining its market position through a series of strategic developments. The pharmaceutical giant finds itself at a pivotal moment, ...

Competition is working, even as the FTC meddles in a takeover fight in a way that helped Pfizer.